Pharma
-
Permission granted by Bristol-Myers Squibb
Bristol Myers to cut 6% of workforce, trim drug pipeline
The layoffs will impact some 2,200 employees, the company said, as it repositions its business ahead of looming patent expirations for top-selling products.
By Ned Pagliarulo • April 25, 2024 -
Permission granted by Biogen
Biogen sees ‘encouraging’ trends for postpartum depression drug
First quarter sales of Zurzuvae doubled consensus estimates, though analysts are skeptical whether the better-than-expected launch will continue.
By Delilah Alvarado • April 24, 2024 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
A stock market run and a flurry of dealmaking have buoyed a sector that spent much of 2023 in a downturn. Can the momentum last?
By BioPharma Dive staff -
William Walker/BioPharma Dive
Sponsored by Allucent[Podcast] Partner for Progress: Strategies for Biotech Success
In this three-part podcast series, hear from seasoned experts from Allucent as they discuss a range of topics, including how small and mid-sized companies can take a more strategic approach to pharmacovigilance, a regulatory & development roadmap for ADCs and RDCs, and pre-MAA/NDA inspection readiness.
April 24, 2024 -
Win McNamee via Getty Images
Former Bristol Myers CEO tapped as Novartis’ next board chair
Giovanni Caforio, who left Bristol Myers in November after eight years as CEO, is set to succeed Novartis’ longtime board chair Joerg Reinhardt next year.
By Delilah Alvarado • April 23, 2024 -
Permission granted by Novartis
Novartis raises forecasts as top drug sales beat Wall Street estimates
Sales of Entresto and Cosentyx grew faster in the first quarter than analysts anticipated, helping drive the quarterly beat and raise.
By Ned Pagliarulo • April 23, 2024 -
Scott Olson via Getty Images
Lilly to buy injectable drug plant in manufacturing ramp-up
The acquisition of a Nexus Pharmaceuticals facility in Wisconsin could help Lilly better meet demand for injectable medicines, like those it makes for diabetes and obesity.
By Delilah Alvarado • April 22, 2024 -
shutterstock.com/ALDECA studio
Sponsored by PhreesiaHow can pharma speed time to treatment? Digital tools can help
Treatment delays can seriously impact patients’ health outcomes. But by leveraging digital tools, pharma can help them find and access specialist care early in their journey.
April 22, 2024 -
Mario Tama via Getty Images
J&J sees mixed performance from new multiple myeloma drugs
Tecvayli sales, which J&J broke out for the first time, surpassed Wall Street forecasts and offset underperformance from Carvykti, which J&J attributed to the "phasing and timing of orders."
By Ned Pagliarulo • April 16, 2024 -
SDI Productions via Getty Images
Sponsored by Sysmex InosticsThe growing role for cfHPV-DNA testing in OPSCC therapeutic development
Learn about why access to robust biomarkers such as cfHPV-DNA is pivotal in determining eligibility, assessing treatment response and detecting recurrence early to improve patient outcomes.
April 15, 2024 -
Permission granted by Vertex Pharmaceuticals
Vertex to buy kidney disease drugmaker Alpine for $4.9B
A proposed $4.9 billion buyout of Alpine Immune Sciences would be the largest ever acquisition for Vertex and align with its "toolkit of technologies" approach to dealmaking.
By Gwendolyn Wu • Updated April 11, 2024 -
Jeenah Moon via Getty Images
RSV vaccinesPfizer, with new study results, seeks to bring RSV shot to adults aged 18-59
The company plans to submit the trial data to regulators in a bid to win approval of its vaccine Abrysvo in adults as young as 18 years old.
By Delilah Alvarado • April 9, 2024 -
Permission granted by Bristol Myers Squibb
Deep DivePsychiatry drugs finally have pharma’s attention. Can they keep it?
Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain.
By Jacob Bell • April 8, 2024 -
Andrii Yalanskyi via Getty Images
Boehringer Ingelheim to lay off staff amid biosimilar challenges
The German pharmaceutical company is “streamlining” its custom-facing teams behind Cyltezo, a copycat version of AbbVie’s immune disease drug Humira.
By Delilah Alvarado • April 5, 2024 -
Peddalanka Ramesh Babu via Getty Images
FDA approves CAR-T therapies from J&J, Bristol Myers for earlier myeloma use
The FDA quickly followed last week’s clearance of Bristol Myers’ Abecma with an OK for J&J’s Carvykti, but gave the rival treatments different labels.
By Ned Pagliarulo • Updated April 8, 2024 -
Kena Betancur via Getty Images
Merck puts KRAS cancer drug competitor to the test
A Phase 3 study will compare Merck’s experimental KRAS inhibitor together with its immunotherapy Keytruda against Keytruda alone in lung cancer.
By Ned Pagliarulo • April 4, 2024 -
stock.adobe.com/TensorSpark
Sponsored by Advanced ClinicalBreaking barriers: Advances and challenges in therapeutic cancer vaccines
The development of cancer vaccines has provided some hope in the battle against cancer worldwide; however, there are still many challenges to overcome when developing these life-saving treatments.
By Christopher Oelkrug, Director of Business Development • April 1, 2024 -
National Cancer Institute, NIH
Bristol Myers says KRAS drug succeeds in key trial
Confirmatory results for Krazati, which Bristol Myers acquired via its buyout of Mirati, could help the drug win full approval while Amgen has been set back.
By Jonathan Gardner • March 29, 2024 -
Courtesy of Roche
Roche autoimmune disease drug disappoints in closely watched trial
Though the medicine hit its goal in a Phase 3 study in myasthenia gravis, the results fell short of expectations in a boost to rival drug developers like Argenx and AstraZeneca.
By Jonathan Gardner • March 21, 2024 -
Sean Gallup via Getty Images
Bayer streamlines pharma leadership team amid company shakeup
The executive team will reportedly shrink from 14 to eight in the latest step in new CEO Bill Anderson’s plan to slash management and reduce “bureaucracy” at the healthcare conglomerate.
By Kristin Jensen • March 21, 2024 -
Sean Gallup via Getty Images
With new data, Bayer readies rival to Astellas menopause drug
Following a third successful Phase 3 trial, the company is planning approval filings for the medicine, which it acquired in a $425 million deal four years ago.
By Delilah Alvarado • March 19, 2024 -
Dr_Microbe via Getty Images
AstraZeneca joins radiopharmaceutical deals spree with $2.4B buyout of Fusion
The deal hands AstraZeneca a prostate cancer drug that’s designed differently than Novartis’ fast-selling Pluvicto and currently in mid-stage testing.
By Ben Fidler • March 19, 2024 -
shutterstock.com/VAlekStudio
Sponsored by VeevaGive HCPs a proactive way to reach your field team: Add inbound
HCPs today want inbound channels for help when they need it. See how you can meet their preferences.
By Paul Shawah, Executive Vice President of Strategy, Veeva • March 18, 2024 -
Permission granted by Bristol-Myers Squibb
Bristol Myers cell therapy wins first-of-its-kind approval
Sold as Breyanzi, the therapy is now cleared for use in certain adults with hard-to-treat forms of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
By Jacob Bell • March 15, 2024 -
Christopher Furlong via Getty Images
AstraZeneca adds another rare disease drug in $800M buyout of startup Amolyt
The deal gives AstraZeneca a prospect in late-stage testing for parathyroidism and bolsters a rare disease portfolio that mainly consists of drugs from Alexion.
By Kristin Jensen • March 14, 2024 -
selvanegra via Getty Images
Roche, following setbacks, turns to its next Alzheimer’s drug
Roche said its experimental Alzheimer’s disease drug trontinemab showed it might be able to clear brain plaques faster than other medicines.
By Jonathan Gardner • March 11, 2024
